0LOV Stock Overview A development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Verastem, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Verastem Historical stock prices Current Share Price US$4.26 52 Week High US$13.94 52 Week Low US$2.14 Beta 0.22 1 Month Change 5.76% 3 Month Change 58.66% 1 Year Change -48.23% 3 Year Change -84.57% 5 Year Change -67.13% Change since IPO -89.56%
Recent News & Updates
Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer Dec 18
Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as A Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer Nov 01
Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting Oct 09
Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer Jul 31 Verastem, Inc. has completed a Follow-on Equity Offering in the amount of $54.995002 million. Jul 25
Verastem, Inc. has completed a Follow-on Equity Offering in the amount of $54.995002 million. See more updates
Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer Dec 18
Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as A Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer Nov 01
Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting Oct 09
Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer Jul 31 Verastem, Inc. has completed a Follow-on Equity Offering in the amount of $54.995002 million. Jul 25
Verastem, Inc. has completed a Follow-on Equity Offering in the amount of $54.995002 million.
Verastem Oncology Announces First Patient Dosed with Gfh375/Vs-7375 in A Phase 1/2 Trial in China as Part of Collaboration with Genfleet Therapeutics Jul 12
Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer May 24
Verastem Oncology Announces Executive Changes Apr 19
Verastem, Inc., Annual General Meeting, May 23, 2024 Apr 13
Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Broader Pipeline in RAS Pathway-Driven Cancers Jan 29
Verastem Oncology Announces Initiation of A Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer Dec 13
Verastem Oncology Announces the Launch of the New Healthcare Professional Component Nov 15 Verastem, Inc. has filed a Follow-on Equity Offering in the amount of $6.510455 million. Nov 10
Verastem Oncology Announces Executive Appointments
Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ in KRAS G12C-Mutant Non-Small Cell Lung Cancer Oct 15
Verastem, Inc. Appoints Daniel Paterson as Class III Director Jul 13
Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer, Effective August 1, 2023 Jul 12
Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer Jul 06 Verastem, Inc. has completed a Follow-on Equity Offering in the amount of $85.018462 million. Jun 17
Verastem Oncology Announces 1-for-12 Reverse Stock Split to Satisfy the Price Requirement for Continued Listing on the Nasdaq Global Market Jun 02
-Verastem Oncology Appoints Karin Tollefson to Board of Directors May 18
Less than half of directors are independent Feb 27 Verastem, Inc. announced that it expects to receive $59.995963 million in funding from BVF Partners L.P. Jan 26
Verastem, Inc. announced that it expects to receive $60 million in funding
Verastem Oncology Appoints Rob Gagnon to the Board of Directors Dec 16
Less than half of directors are independent Nov 30
Third quarter 2022 earnings released: US$0.092 loss per share (vs US$0.13 loss in 3Q 2021) Nov 05
Verastem Oncology Appoints Anil Kapur to Board of Directors Oct 21
Verastem Oncology Announces RAMP VS-6766 Clinical Trials Oct 06
Second quarter 2022 earnings released: US$0.12 loss per share (vs US$0.098 loss in 2Q 2021) Aug 08
Verastem, Inc.(NasdaqGM:VSTM) dropped from Russell 2000 Dynamic Index Jun 26
Verastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 +/- Defactinib in Low-Grade Serous Ovarian Cancer Jun 07
First quarter 2022 earnings released: US$0.091 loss per share (vs US$0.088 loss in 1Q 2021) May 11
Less than half of directors are independent Apr 29
Verastem, Inc., Annual General Meeting, May 12, 2022 Apr 02
Less than half of directors are independent Apr 01
Full year 2021 earnings released: US$0.41 loss per share (vs US$0.44 loss in FY 2020) Mar 30
Verastem, Inc. Announces Management Changes Mar 29
CEO & Director recently sold US$53k worth of stock Jan 06
Forecast to breakeven in 2024 Jan 01
Third quarter 2021 earnings released: US$0.13 loss per share (vs US$0.078 profit in 3Q 2020) Nov 06
Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates and Progression-Free Survival Presented at ESMO 2021 Sep 21
No longer forecast to breakeven Aug 04
Second quarter 2021 earnings released: US$0.098 loss per share (vs US$0.14 loss in 2Q 2020) Aug 03
Forecast to breakeven in 2023 Jul 05 Verastem, Inc.(NasdaqGM:VSTM) dropped from Russell 3000E Value Index
Verastem Oncology Receives Breakthrough Therapy Designation for VS-6766 with Defactinib in Recurrent Low-Grade Serous Ovarian Cancer May 25
First quarter 2021 earnings released: US$0.088 loss per share (vs US$0.35 loss in 1Q 2020) May 13
Verastem, Inc. Reports Updated Data from the LGSOC Cohort of the Ongoing, Investigator-Sponsored Phase 1/2 Frame Study Evaluating Vs-6766 in Combination with Defactinib in Patients with Recurrent LGSOC May 12
Full year 2020 earnings released: US$0.44 loss per share (vs US$2.00 loss in FY 2019) Mar 20
Verastem, Inc. Appoints Frank Neumann as Chief Medical Officer Jan 08
Verastem, Inc. Initiates Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Previously Treated KRAS Mutant Non-Small Cell Lung Cancer Dec 17
Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer Dec 01 Secura Bio, Inc. completed the acquisition of Global Commercial and Development Rights of COPIKTRA from Verastem, Inc. (NasdaqGM:VSTM). Shareholder Returns 0LOV GB Biotechs GB Market 7D -10.0% -5.1% -2.2% 1Y -48.2% -24.5% 2.4%
See full shareholder returns
Return vs Industry: 0LOV underperformed the UK Biotechs industry which returned -24.5% over the past year.
Return vs Market: 0LOV underperformed the UK Market which returned 2.4% over the past year.
Price Volatility Is 0LOV's price volatile compared to industry and market? 0LOV volatility 0LOV Average Weekly Movement 16.6% Biotechs Industry Average Movement 7.0% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.5% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: 0LOV's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0LOV's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205.
Show more Verastem, Inc. Fundamentals Summary How do Verastem's earnings and revenue compare to its market cap? 0LOV fundamental statistics Market cap US$186.48m Earnings (TTM ) -US$93.45m Revenue (TTM ) US$10.00m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0LOV income statement (TTM ) Revenue US$10.00m Cost of Revenue US$0 Gross Profit US$10.00m Other Expenses US$103.45m Earnings -US$93.45m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -2.10 Gross Margin 100.00% Net Profit Margin -934.54% Debt/Equity Ratio 126.2%
How did 0LOV perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 20:11 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Verastem, Inc. is covered by 27 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution James Molloy Alliance Global Partners Matthew Cross Alliance Global Partners Kalpit Patel B. Riley Securities, Inc.
Show 24 more analysts 
